摘要
目的:观察肠炎宁胶囊治疗急性感染性腹泻的临床效果。方法:100例急性感染性腹泻患者依据随机数表法分为试验组与对照组,每组各50例。对照组给予盐酸小檗碱片口服,试验组给予肠炎宁胶囊口服。比较两组患者治疗后症状体征变化、中医证候疗效、腹痛与腹泻症状消失时间、血浆C反应蛋白(CRP)变化情况;同时观察用药后两组出现的不良事件。结果:用药3 d后,试验组患者临床总有效率和中医证候总有效率为96.00%和98.00%,明显优于对照组(82.00%和86.00%),两组患者比较差异有统计学意义(P<0.05);试验组患者平均止痛、止泻所用时间均短于对照组,组间比较差异均有统计学意义(P<0.05);两组治疗后血浆CRP与治疗前相比均有明显下降,且试验组明显低于对照组,差异有统计学意义(P<0.05)。治疗期间,试验组和对照组所有患者均无严重不良事件和不良反应发生。结论:肠炎宁胶囊用于急性感染性腹泻患者疗效确切,安全性好。
Objective:To investigate the clinical efficacy of Changyanning capsule in the treatment of acute infectious diarrhea.Methods:100 patients with acute infectious diarrhea were randomly divided into the experimental group and the control group according to random number table,each group had 50 cases.The control group was given oral administration of Berberine Hydrochloride tablets,and the experimental group was given oral treatment of Changyanning capsule.The changes of symptoms,curative effect of TCM syndromes,the disappearance time of abdominal pain and diarrhea symptoms,and plasma C reactive protein(CRP)were compared between the two groups.At the same time,the adverse events in the two groups were observed.Results:After 3 days of medication,the total effective rate and total effective rate of TCM Syndrome in the experimental group were 96.00%and 98.00%,which were obviously better than those in the control group(82.00%and 86.00%).The difference between the two groups was statistically significant(P<0.05).The average analgesic and antidiarrheal time in the experimental group was shorter than that in the control group,and the differences between the two groups were statistically significant(P<0.05).After treatment,the plasma CRP of two groups decreased significantly,and the plasma CRP in the experimental group was lower than that in the control group(P<0.05).During the treatment,no serious adverse events and adverse reactions occurred in the experimental group and the control group.Conclusions:Changyanning capsuleIt is effective and safe for patients with acute infectious diarrhea.
作者
刘瑛琦
王燕南
齐建新
LIU Ying-qi;WANG Yan-nan;QI Jian-xin(Department of Infectious Diseases,The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine,Harbin 150001,Heilongjiang;Hainan Hulu Pharmaceutical Group Limited by Share Ltd;Hainan Beverly Pharmaceutical Import&Export Co.Ltd,Haikou 570100,Hainan,China)
出处
《川北医学院学报》
CAS
2018年第1期53-55,共3页
Journal of North Sichuan Medical College
基金
黑龙江省高校科技创新团队计划项目(2013TD007)